CASE REPORT
Anti-integrin treatment as an effective alternative for a patient with ulcerative colitis
1
Student Research Association of Paediatric Emergency Medicine, Medical University of Warsaw, Warsaw, Poland
2
Department of Paediatric Gastroenterology and Nutrition, Medical University of Warsaw, Warsaw, Poland
Submission date: 2022-05-08
Final revision date: 2022-06-12
Acceptance date: 2022-06-13
Publication date: 2022-12-30
Pediatr Pol 2022;97(4):347-350
KEYWORDS
TOPICS
ABSTRACT
Paediatric ulcerative colitis (UC) has a tendency to run in an extensive manner, with frequent exacerbations. As a result, treatment of paediatric patients is a complex process demanding thorough evaluation, careful monitoring, and selection of appropriate medication. We present a case report of UC in an 11-year-old boy diagnosed at the age of 7 years. During 3 years of treatment many therapeutic methods were used, but none brought a long-lasting therapeutic effect. Due to exhaustion of available therapeutic options, off-label treatment with vedolizumab was introduced. Currently, in his 15th month of the therapy, the patient remains in remission. This case, in line with the available literature, indicates that there might be a need to include vedolizumab to the UC standard treatment regimens. Moreover, it should also be considered for inclusion in funding programs of national health insurance companies. It is of a crucial importance for patients because in some cases it remains the last treatment option.
REFERENCES (17)
1.
Lynch WD, Hsu R. Ulcerative colitis. StatPearls [Internet]. StatPearls Publishing 2021.
2.
Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011; 17: 423-439.
3.
Aloi M, D’Arcangelo G, Pofi F, et al. Presenting features and disease course of pediatric ulcerative colitis. J Crohns Colitis 2013; 7: e509-15.
4.
Martinelli M, Giugliano FP, Russo M, et al. The changing face of pediatric ulcerative colitis: a population-based cohort study. J Pediatr Gastroenterol Nutr 2018; 66: 903-908.
5.
Kim JY, Park DI, Han DS, et al. Comparing the clinical outcomes of young-onset and adult-onset ulcerative colitis: a multi-center Korean Association for the Study for Intestinal Diseases study. Korean J Intern Med 2017; 32: 69-78.
6.
Jang J, Lee SH, Jeong IS, et al. Clinical characteristics and long-term outcomes of pediatric ulcerative colitis: a single-center experience in Korea. Gut Liver 2022; 16: 236-245.
7.
Ihekweazu FD, Fofanova T, Palacios R, et al. Progression to colectomy in the era of biologics: a single center experience with pediatric ulcerative colitis. J Pediatr Surg 2020; 55: 1815-1823.
8.
Rinawi F, Assa A, Hartman C, et al. Long-term extent change of pediatric-onset ulcerative colitis. J Clin Gastroenterol 2018; 52: 326-332.
9.
Bolia R, Rajanayagam J, Hardikar W, et al. Impact of changing treatment strategies on outcomes in pediatric ulcerative colitis. Inflamm Bowel Dis 2019; 25: 1838-1844.
10.
Rezaie A. Vedolizumab, a gut-specific monoclonal antibody, renews hope for an alternative to anti-TNF therapy in inflammatory bowel diseases. Ann Gastroenterol 2014; 27: 179-180.
12.
Garcia-Romero R, Martinez de Zabarte Fernandez JM, Pujol-Muncunill G, et al. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study. Eur J Pediatr 2021; 180: 3029-3038.
13.
Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710.
14.
Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711-721.
15.
Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care – an evidence-based guideline from European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 67: 257-291.
16.
Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 2: acute severe colitis – an evidence-based consensus guideline from the european crohn’s and colitis organization and the european society of paediatric gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol Nutr 2018; 67: 292-310.
17.
Hyams JS, Turner D, Cohen SA, et al. Pharmacokinetics, safety, and efficacy of intravenous vedolizumab in paediatric patients with ulcerative colitis or crohn’s disease: results from the phase 2 HUBBLE study. J Crohns Colitis 2022; 16: 1243-1254.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
